PathAI AISight vs Tempus Digital Pathology
PathAI AISight and Tempus Digital Pathology both compete in pathology, but answer different questions. PathAI AISight is our pick for IMS + AI platform: Open IMS with AISight Dx + biopharma diagnostic services. Tempus Digital Pathology earns the Paige acquisition (Aug 2025) slot: Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI. The right choice depends on whether your priority is ims + ai platform or paige acquisition (aug 2025).
- Pathology
- 02
- May 23, 2026
PathAI AISight
by PathAI · founded 2016
Open IMS platform with AISight Dx + biopharma diagnostic services.
- Enterprise.
- —
Tempus Digital Pathology
by Tempus AI
Paige Predict 123-biomarker pan-cancer suite (Tempus acquired Paige 2025).
- Enterprise + per-test.
- FDA 510(k) / CE-IVDR
How PathAI AISight and Tempus Digital Pathology compare
Pricing, compliance, and integrations sourced from vendor documentation. Verified May 23, 2026.
| Spec | PathAI AISight | Tempus Digital Pathology |
|---|---|---|
| Pricing | Enterprise. | Enterprise + per-test. |
| Free tier | Yes | Yes |
| HIPAA | No / unverified | No / unverified |
| SOC 2 Type II | No / unverified | No / unverified |
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | — |
| HQ | US | US |
| Best for | Best open IMS + AI platform | Best after Paige acquisition (Aug 2025) |
Scroll horizontally to see both columns.
When to pick each one
Best open IMS + AI platform
Open IMS with AISight Dx + biopharma diagnostic services.
- Vendor-agnostic IMS appeals to mixed-vendor labs
- Strong biopharma R&D revenue
Best after Paige acquisition (Aug 2025)
Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI.
- NASDAQ:TEM
- Most clinical-validation depth
- FDA + CE-IVDR cleared modules
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.
/best-ai-pathology